| 000 | 01646 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250513040054.0 | ||
| 264 | 0 | _c19930224 | |
| 008 | 199302s 0 0 eng d | ||
| 022 | _a0021-9738 | ||
| 024 | 7 |
_a10.1172/JCI116161 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aCaligiuri, M A | |
| 245 | 0 | 0 |
_aSelective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2. _h[electronic resource] |
| 260 |
_bThe Journal of clinical investigation _cJan 1993 |
||
| 300 |
_a123-32 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. | ||
| 650 | 0 | 4 |
_aAntibody-Dependent Cell Cytotoxicity _xdrug effects |
| 650 | 0 | 4 |
_aAntigens, CD _xanalysis |
| 650 | 0 | 4 |
_aAntigens, Differentiation, T-Lymphocyte _xanalysis |
| 650 | 0 | 4 | _aCD56 Antigen |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInfusions, Intravenous |
| 650 | 0 | 4 |
_aInterleukin-2 _xadministration & dosage |
| 650 | 0 | 4 |
_aKiller Cells, Natural _xdrug effects |
| 650 | 0 | 4 |
_aNeoplasms _xblood |
| 650 | 0 | 4 |
_aReceptors, Interleukin-2 _xanalysis |
| 650 | 0 | 4 |
_aRecombinant Proteins _xadministration & dosage |
| 650 | 0 | 4 | _aTime Factors |
| 700 | 1 | _aMurray, C | |
| 700 | 1 | _aRobertson, M J | |
| 700 | 1 | _aWang, E | |
| 700 | 1 | _aCochran, K | |
| 700 | 1 | _aCameron, C | |
| 700 | 1 | _aSchow, P | |
| 700 | 1 | _aRoss, M E | |
| 700 | 1 | _aKlumpp, T R | |
| 700 | 1 | _aSoiffer, R J | |
| 773 | 0 |
_tThe Journal of clinical investigation _gvol. 91 _gno. 1 _gp. 123-32 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1172/JCI116161 _zAvailable from publisher's website |
| 999 |
_c7678024 _d7678024 |
||